A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)

Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2-positive agents like trastuzumab alone, promising results have been observed when combined with other synergisticall...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Akshit Chitkara, Muhammad Bakhtiar, Ibrahim Halil Sahin, Dennis Hsu, Janie Zhang, FNU Anamika, Mahnoor Mahnoor, Rabeea Ahmed, Sepideh Gholami, Anwaar Saeed
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2023-09-01
סדרה:	Current Oncology
נושאים:	trastuzumab deruxtecan HER2-positive tyrosine kinase inhibitors metastatic colorectal cancer
גישה מקוונת:	https://www.mdpi.com/1718-7729/30/9/600
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!